Effective and safe systemic treatment for advanced hepatocellular carcinoma (HCC) with severe underlying cirrhosis is not yet available. Sorafenib, an oral multikinase inhibitor, has proved to be effective in the treatment of patients affected by HCC with Child-Pugh class A liver function. For patients with cirrhosis-associated HCC having Child-Pugh class B and C liver function, no systemic treatments of documented efficacy and safety exist. We report a case of metastatic HCC associated with Child-Pugh class B cirrhosis that was treated with low, “metronomic” doses of capecitabine (1000 mg/day continuously). This treatment was effective and well tolerated and the response was maintained for 18 months. Metronomic capecitabine may represent a possible alternative in the treatment of those patients with advanced cirrhosis-associated HCC who cannot be treated with sorafenib. Free full text available at www.tumorionline.it
Von DeliusS., LerschC., MayrM., StockK., Schulte-FrohlindeE., SchmidR.M., EckelF.: Capecitabine for treatment of advanced hepatocellular carcinoma. Hepatogastroenterology, 54: 2310–2314, 2007.
11.
ZhangQ., KangX., YangB., WangJ., YangF.: Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice. Cancer Biother Radiopharm, 23: 647–653, 2008.
12.
KerbelR.S., KamenB.A.: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer, 4: 423–436, 2004.
13.
ParkS.T., JangJ.W., KimG.D., ParkJ.A., HurW., WooH.Y., KimJ.D., KwonJ.H., YooC.R., BaeS.H., ChoiJ.Y., YoonS.K.: Beneficial effect of metronomic chemotherapy on tumor suppression and survival in a rat model of hepatocellular carcinoma with liver cirrhosis. Cancer Chemother Pharmacol, 65: 1029–37, 2010.
ColleoniM., RoccaA., SandriM.T., ZorzinoL., MasciG., NolèF., PeruzzottiG., RobertsonC., OrlandoL., CinieriS., de BraudF., VialeG., GoldhirschA.: Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer. Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol, 13: 73–80, 2002.
16.
ColleoniM., OrlandoL., SannaG., RoccaA., MaisonneuveP., PeruzzottiG., GhisiniR., SandriM.T., ZorzinoL., NolèF., VialeG., GoldhirschA.: Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol, 17: 232–238, 2006.
17.
KamatA.A., KimT.J., LandenC.N.Jr., LuC., HanL.Y., LinY.G., MerritW.M., ThakerP.H., GershensonD.M., BischoffF.Z., HeymachJ.V., JaffeR.B., ColemanR.L., SoodA.K.: Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res, 67: 281–288, 2007.
18.
NeliusT., KlatteT., de RiesaW., HaynesA., FilleurS.: Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cycophosphamide-based metronomic chemotherapy. Med Oncol, 27: 363–367, 2010.
19.
CalvaniN., OrlandoL., NacciA., SponzielloF., CinefraM., CinieriS.: Metronomic chemotherapy against cancer: from paradigm to clinical practice?Tumori, 95: 843–845, 2009.
